Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience

被引:29
|
作者
Chen, Rui-fang [1 ]
Li, Jun [1 ]
Zhu, Ting-ting [1 ]
Yu, Hai-lin [1 ]
Lu, Xin [1 ]
机构
[1] Fudan Univ, Dept Gynecol Oncol, Obstet & Gynecol Hosp, 128 Shen Yang Rd Yangpu Dist, Shanghai 200000, Peoples R China
基金
上海市自然科学基金;
关键词
Borderline ovarian tumors (BOTs); Fertility sparing surgery; Surgical procedure; Surgical approach; Staging; Chemotherapy; Recurrence; Pregnancy; PROGNOSTIC-FACTORS; CONSERVATIVE TREATMENT; SURGICAL-MANAGEMENT; ADJUVANT TREATMENT; FOLLOW-UP; RECURRENCE; IMPACT; DIAGNOSIS; NEOPLASMS; SURVIVAL;
D O I
10.1186/s13048-016-0226-y
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Fertility-sparing surgery for patients with borderline ovarian tumors (BOTs) is still controversial. This study aimed to evaluate the oncological safety and fertility benefits in conservative surgery, as well as efficiency of surgical procedures and approaches. Results: In total 122 patients with BOTs, four types of fertility-sparing surgery were performed: unilateral adnexectomy (UA, n = 47), unilateral cystectomy (UC, n = 59), unilateral adnexectomy + contralateral cystectomy (UA + CC, n = 7) and bilateral cystectomy (BC, n = 9). Fifty-two (42.6 %) patients had undergone laparoscopy, while 70 (57.4 %) had undergone laparotomy. After a median follow-up of 58.0 months, eight patients (6.6 %) relapsed in average of 25.9 months. Only one patient progressed to invasive cancer. None died within our observational period. Univariate analysis showed that patients with elevated CA125, bilateral tumors, extra-ovary tumor or mucinous type tended to replase in shorter time (p < 0.05). Among all cases, 45 patients attempted to conceive and 34 (75.6 %) patients had successful pregnancy. The recurrence rates were successively increased (2.1 %, 6.8 %, 14.3 %, and 22.2 %), the recurrence interval were shortened (48.0, 25.3, 26.0 and 21.2 months) and the subsequent fertility rates were 76.9 %, 77.3 %, 66.7 % and 71.4 % in UA, UC, UA + CC, and BC groups, respectively. As for surgical approaches, three patients (5.8 %) relapsed in 26.3 months in the laparoscopy group and five (7.1 %) in 25.5 months in the laparotomy group. The subsequent fertility rate was higher in laparoscopy group (88.9 %) than in laparotomy group (66.7 %). In our study, 38 patients underwent staging surgery. Two patients (5.3 %) recurrent in average of 21.0 months, and the subsequent pregnancy rate of staging surgery group was 61.5 %. Twelve patients received adjuvant chemotherapy but they didn't get any benefit from it, both in term of recurrence (8.3 %, 26.0 months) and subsequent pregnancy rate (75.5 %). Conclusion: Fertility-sparing surgery is safe and beneficial for most young BOTs. UA through laparoscopy should be recommended as the first choice. To the patients with bilateral tumors, elevated CA125, extra-ovary tumor or mucinous type, conservative surgery should be carefully chosen and subsequent pregnancy should be attempted in short term. In addition, the benefit of comprehensive surgical staging is to be further investigated and adjuvant chemotherapy is not recommended.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience
    Rui-fang Chen
    Jun Li
    Ting-ting Zhu
    Hai-lin Yu
    Xin Lu
    Journal of Ovarian Research, 9
  • [2] FERTILITY-SPARING SURGERY IN PATIENTS WITH BORDERLINE OVARIAN TUMORS AND REPRODUCTIVE OUTCOMES
    Helmut, P.
    Harter, P.
    Ataseven, B.
    Heitz, F.
    Prader, S.
    Schneider, S.
    Heikaus, S.
    Traut, A.
    du Bois, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A47 - A48
  • [3] FERTILITY-SPARING SURGERY (FSS) IN PATIENTS WITH BORDERLINE OVARIAN TUMORS (BOT)
    Vdovichenko, N.
    Harter, P.
    Ataseven, B.
    Heitz, F.
    Prader, S.
    Schneider, S.
    Kurzeder, K.
    Heikaus, S.
    Weikel, W.
    Fisseler-Eckhoff, A.
    Traut, A.
    du Bois, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1568 - 1568
  • [4] Fertility-sparing surgery (FSS) in patients with borderline ovarian tumors (BOT)
    Vdovichenko, N.
    Ataseven, B.
    Heitz, F.
    Prader, S.
    Schneider, S.
    Kurzeder, C.
    Heikaus, S.
    Weikel, W.
    Fisseler-Eckhoff, A.
    Alexander, T.
    du Bois, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 92 - 92
  • [5] Fertility preservation for women with borderline ovarian tumors: fertility-sparing surgery
    Kim, S. Samuel
    FERTILITY AND STERILITY, 2021, 115 (01) : 83 - 84
  • [6] Borderline ovarian tumors, fertility-sparing surgery and pregnancy outcome
    Frega, A.
    Coluccia, A. C.
    Di Martino, G.
    Catalano, A.
    Milazzo, G. N.
    Assorgi, C.
    Manzara, F.
    Romeo, G. D.
    Gentile, M.
    Marziani, R.
    Moscarini, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (02) : 281 - 284
  • [7] Pregnancy after fertility-sparing surgery for borderline ovarian tumors
    Lian, Chengying
    Chen, Xiujuan
    Ni, Yihua
    Huang, Xiaochen
    Lin, Yuan
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2016, 134 (03) : 282 - 285
  • [8] Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors
    Plett, Helmut
    Harter, Philipp
    Ataseven, Beyhan
    Heitz, Florian
    Prader, Sonia
    Schneider, Stephanie
    Heikaus, Sebastian
    Fisseler-Eckhoff, Annette
    Kommoss, Friedrich
    Lax, Sigurd F.
    Staebler, Annette
    Traut, Alexander
    du Bois, Andreas
    GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 411 - 417
  • [9] Second fertility-sparing surgery and fertility-outcomes in patients with recurrent borderline ovarian tumors
    Wang, Lifei
    Zhong, Qian
    Tang, Qin
    Wang, Hongjing
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2022, 306 (04) : 1177 - 1183
  • [10] Second fertility-sparing surgery and fertility-outcomes in patients with recurrent borderline ovarian tumors
    Lifei Wang
    Qian Zhong
    Qin Tang
    Hongjing Wang
    Archives of Gynecology and Obstetrics, 2022, 306 : 1177 - 1183